OSTEOFAB PATIENT SPECIFIC CRANIAL DEVICE

K121818 · Oxford Performance Materials · GXN · Feb 7, 2013 · Neurology

Device Facts

Record IDK121818
Device NameOSTEOFAB PATIENT SPECIFIC CRANIAL DEVICE
ApplicantOxford Performance Materials
Product CodeGXN · Neurology
Decision DateFeb 7, 2013
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 882.5330
Device ClassClass 2
AttributesTherapeutic

Intended Use

The OsteoFab™ Patient Specific Cranial Device (OPSCD) intended for the replacement of bony voids in the cranial skeleton.

Device Story

OsteoFab™ Patient Specific Cranial Device (OPSCD) is a patient-specific implant for cranial bone defects. Input data consists of patient CT imaging; processed via computer-aided design (CAD) to determine implant dimensions. Device is manufactured using laser sintering of OXPEKK polymer. OPSCD is a non-load bearing, single-use device; attached to native bone using commercially available cranioplasty fixation systems. Used in clinical settings by physicians to restore cranial anatomy. Benefits include precise anatomical fit based on patient-specific imaging, facilitating reconstruction of cranial voids.

Clinical Evidence

Bench testing only. Testing included biocompatibility (ISO 10993), endotoxin testing (USP 85), and mechanical characterization (tensile strength, Young's modulus, elongation at break) across varying thicknesses (1mm, 2mm, 3.2mm, 4mm) and pore configurations. All results met pre-defined QC acceptance criteria.

Technological Characteristics

Material: OXPEKK polymer. Manufacturing: Laser sintering. Form factor: Patient-specific, custom-sized based on CT data. Thickness range: 1mm minimum. Through-hole range: 2mm to 5mm diameter with 2mm minimum spacing. Sterilization: Non-sterile (validated instructions provided).

Indications for Use

Indicated for the replacement of bony voids in the cranial skeleton. No specific age or gender restrictions provided.

Regulatory Classification

Identification

A preformed nonalterable cranioplasty plate is a device that is implanted in a patient to repair a skull defect and is constructed of a material, e.g., stainless steel or vitallium, that cannot be altered or reshaped at the time of surgery without changing the chemical behavior of the material.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image shows a logo with the letters OPM. The O is a circle with a cross inside, surrounded by a dotted square. The P is a circle with a square inside, and the M is a triangle with two lines inside. K121818 page 1 of 5 # 5 - 5 1 0 (k) Summary Statement as Required by Title 21 CFR 807.92 FEB 7 2013 510(k) Submitter: Oxford Performance Materials, LLC 30 South Satellite Road South Windsor, CT 06074 USA 1-860-698-9300 Contact Person: Leigh Ayres, Director of Scientific & Regulatory Affairs Date of 510(k) summary preparation: December 18, 2012 Proprietary Name: OsteoFab™ Patient Specific Cranial Device Common or Usual Name: Patient Specific Cranial Implant Classification: Title 21 CFR 882.5330; Preformed Non-Alterable Cranioplasty Plate; Class II Panel: Neurology Product Code: GXN Predicate Devices: Kelyniam Custom Skull Implant (K103582), Synthes Patient Specific Cranial Implant (K053199), Osteo-Symbionics Patient Specific Cranial Implant (K072601), MedCAD AccuShape PEEK Patient Specific Implant (K110684), and Osteo-Symbionics Patient Specific #### Description of the Device Cranial Implant (K121102) An OsteoFab™ Patient Specific Cranial Device (OPSCD) is built individually for each patient to correct defects in cranial bone. The OPSCD is constructed with the use of the patient's CT imaging data and computer aided design to determine the dimensions of each implant. The OPSCD is built by a LASER sintering machine. The OPSCD is attached to native bone with commercially available cranioplasty fixation systems. The OPSCD is a non-load bearing single use device and it is non-sterilization instructions documented in the package insert have been validated. #### Intended Use Statement The OsteoFab™ Patient Specific Cranial Device (OPSCD) intended for the replacement of bony voids in the cranial skeleton. #### Endotoxicity Non-sterillized OsteoFab™ Patient Specific Cranial Device (OPSCD) test specimens were subjected to a Limulus Amebocyte Lysate (LAL) assay according to USP 85 and the results of the testing showed that bacterial endotoxin levels were lower than the detection limit of 2.15 EU/device. > Section 5 OPSCD 510(k) Summary 2012Dec18 Page 1 of 5 30 South South Windsor, CT 06074 USA • T: +1.860.698.9300 • F: +1.860.698.9978 • www.oxfordpm.com {1}------------------------------------------------ ## Biocompatibility Biocompatibility tests were selected according to the FDA guidance document: "Use of International Standard 150-10993, "Biological Evaluation of Medical Devices Part 1: Evaluation and Testing" (1995) and the test results obtained from test specimens were found to be within acceptance criteria described in the standards. ## Performance Testing - Bench Testing The test suite for the final quality control (QC) testing of the OsteoFab™ Patient Specific Cranial Device (OPSCD) includes glass transition temperature (Tg), Fourier transform infrared spectroscopy (FTIR), specific gravity, and tensile strength. The final QC specifications for those tests were determined from 23 builds. TABLE 1 shows the mean, standard deviation, the standard deviation multiplied by three, the acceptance criteria, and the formula for the acceptance criteria. | | Tg<br>(20°C/min) | FTIR | Average<br>Specific<br>Gravity | Average<br>Tensile<br>Stress at<br>Break (X-<br>orientation)<br>(KPSI) | Average<br>Tensile<br>Elongation<br>@ Break<br>(%) | Average<br>Young's<br>Modulus of<br>Elasticity<br>(KPSI) | |----------------------------------------------|------------------|------------------------------------------------------|--------------------------------|------------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------------| | mean | 160.70 | 96.68 | 1.28 | 12.04 | 2.52 | 541.61 | | SDEV | 2.10 | 0.73 | 0.01 | 1.10 | 0.35 | 93.89 | | 3SD | 6.30 | 2.19 | 0.03 | 3.27 | 1.05 | 279 | | Acceptance<br>Criteria | 154-167 | ≥95% Match | 1.25-1.31 | ≥8.77 | ≤3.6% | ≥262 | | Formula for<br>the<br>Acceptance<br>Criteria | Mean +/-<br>3SD | ≥95% Match<br>to a<br>Designated<br>PEKK<br>Standard | Mean +/-<br>3SD | Mean - 3SD | Mean +<br>3SD | Mean - 3SD | TABLE 1: Summary Statistics of 23 Builds The OPSCD test specimens from the 23 builds which were subjected to tensile strength testing were 3.2 mm thick. In order to determine the minimum thickness for an OPSCD..three sets (5 specimens each) of tensile bars that were 1, 2, and 4 mm thick were built. The average tensile strength data for each size is compared to the final QC release acceptance criteria (see TABLE 2). > Section 5 OPSCD 510(k) Summary 2012Dec18 Page 2 of 5 {2}------------------------------------------------ All three sizes (1, 2, and 4 mm) of test specimens are substantially equivalent to the 3.2 mm final QC test specimen because the data obtained was within the final QC acceptance criteria. Based on the measurements obtained, the minimum thickness of an OPSCD is 1 mm. | Sample Description | Average Tensile Stress at<br>Break (X-orientation)<br>(KPSI) | Average<br>Tensile<br>Elongation @<br>Break<br>(%) | Average Young's<br>Modulus of<br>Elasticity (KPSI) | |------------------------------------------|--------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------| | 1 mm thickness (average) | 10.5 | 2.4 | 329 | | 2 mm thickness (average) | 10.8 | 2.4 | 409 | | 4 mm thickness (average) | 11.6 | 2.4 | 490 | | Release Criteria for 3.2 mm<br>thickness | $ \ge 8.77 $ | $ \le 3.6 $ | $ \ge 262 $ | TARIE 7. Summ and Statistics of the 1 7 and 4 mm Thick Tost S Test specimens were also built to determine the range of pore (through hole) sizes and the minimum spacing of through holes. · These test specimens were 4 mm thick and each had more than 10 through holes. Based on the measurements obtained, the range of through holes that can be built is 2 mm to 5 mm and the minimum spacing of through holes is 2 mm. TABLE 3 and TABLE 4 show the average of the through hole size measurements and the average of the spacing between through hole measurements, respectively. | TABLE 3: Vernier Caliper Measurements of the Diameter of Through Holes | | | |------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------| | | | | | | 5 mm Through Hole Test<br>Specimen with 5 mm Spacing<br>(Diameter in mm) | 2 mm Through Hole Test<br>Specimen with 2 mm Spacing<br>(Diameter in mm) | | Average (n=10) | 4.74 | 1.92 | | Standard Deviation | 0.03 | 0.05 | | Nominal Value with Tolerance | 5.00 (4.50 – 5.50) | 2.00 (1.50 - 2.50) | | | TABLE 4: Vernier Caliper Measurements of the Spacing between Through Holes | | |------------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------------| | | .5 mm Through Hole Test<br>Specimen with 5 mm Spacing<br>(Spacing in mm) | 2 mm Through Hole Test<br>Specimen with 2 mm Spacing<br>(Spacing in mm) | | Average (n=10) | 4.81 | 1.79 | | Standard Deviation | 0.02 | 0.03 | | Nominal Value with Tolerance | 5.00 (4.50 - 5.50) | 2.00 (1.50 - 2.50) | ്Section 5 OPSCD 510(k) Summary 2012Dec18 Page 3 of 5 {3}------------------------------------------------ K121318 page 4 of 5 #### Substantial Equivalence Discussion The OsteoFab™ Patient Specific Cranial Device (OPSCD) is substantially equivalent to five other preformed nonalterable cranioplasty plates: the Kelyniam custom Skull Implant, the Synthes Patient Specific Cranial Implant, the Osteo-Symbionics Patient Specific Cranial Implant, the MedCAD AccuShape PEEK Patient Specific Implant, and the Osteo-Symbionics Patient Specific Cranial Implant. The intended use statement for the OPSCD is within the scope of application for the five predicate devices. The intended use statements of the Synthes and Osteo-Symbionics devices apply to cranial and craniofacial bone. The intended use statement of the OPSCD is limited to cranial skeleton. All five predicate devices are fabricated from polymers, each is custom sized to the patient, and they are sold non-sterile. The substantial equivalence Information on the subject and predicate devices is summarized on the substantial equivalence matrix (TABLE 5). The substantial equivalence matrix shows that the characteristics listed for the subject (OPSCD) and the five predicate devices are substantially equivalent. #### Section 5 OPSCD 510(k) Summary 2012Dec18 Page 4 of 5 {4}------------------------------------------------ Image /page/4/Picture/0 description: The image shows a logo with the letters OPM. The O is inside a square with a circle inside of it. The P is a bolded letter inside of a circle. The M is made up of lines and triangles. # TABLE 5: Substantial Equivalence Matrix | Characteristic | OsteoFab™<br>Patient Specific<br>Cranial Device<br>(Subject Device) | Kelyniam<br>Custom Skull<br>Implant<br>(K103582) | Synthes<br>Patient Specific<br>Cranial Implant<br>(K053199) | Osteo-<br>Symbionics<br>Patient Specific<br>Cranial Implant<br>(K072601) | MedCAD<br>AccuShape PEEK<br>Patient Specific<br>Implant<br>(K110684) | Osteo-<br>Symbionics<br>Patient Specific<br>Cranial Implant<br>(K121102) | |-----------------------------|---------------------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------|-----------------------------------------------------------------------------------------| | Intended Use | Replace bony<br>voids in the<br>cranial skeleton | Replace bony<br>voids in the<br>cranial skeleton | Replace bony<br>voids in the<br>cranial<br>craniofacial<br>skeleton | Corrects defects<br>in craniofacial<br>bone | Correct<br>defects/replace<br>bony voids in<br>the cranial<br>skeleton | Designed<br>individually for<br>each patient to<br>correct defects<br>in cranial bone | | Materials | ΟΧΡΕΚΚ | PEEK-OPTIMA<br>LT1 | PEEK Optima-<br>LT1 | Polymethyl<br>Methacrylate<br>(PMMA) | PEEK | PEEK | | Technical<br>Specifications | Custom sized to<br>each patient<br>utilizing<br>CT data | Custom sized to<br>each patient<br>utilizing<br>CT data | Custom sized to<br>each patient | Plate - custom<br>sized to each<br>patient | Custom sized to<br>each patient<br>utilizing CT data | Manufactured<br>one at a time to<br>custom-order<br>based upon the<br>patient's CT scan | | Sterilization | Non-sterile | Non-sterile | Non-sterile | Non-sterile | Non-sterile | Non-sterile | Section 5 OPSCD 510(k) Summary 2012Dec18 Page 5 of 5 Oxford Performance Materials . . . . . . . . . . . . 0 South Solellie Rood • South Windsor, CT 06074 USA • T: +1.860.698.9978 • www.oxfordpm.com K121818 page 5 of 5 {5}------------------------------------------------ Image /page/5/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three tail feathers, enclosed in a circle. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged around the top of the circle. Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 FEB 26 2013 Oxford Performance Materials % Ms. Leigh Avres Director of Scientific and Regulatory Affairs 30 South Satellite Road South Windsor, CT 06074 Re: K121818 Trade/Device Name: OsteoFabTM Patient Specific Cranial Device Regulation Number: 21 CFR 886.5330 Regulation Name: Preformed nonalterable cranioplasty plate Regulatory Class: Class II Product Code: GXN Dated: December 18, 2012 Received: December 28, 2012 Dear Ms. Ayres: This letter corrects our substantially equivalent letter of February 7, 2013. We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {6}------------------------------------------------ Page 2 - Ms. Leigh Ayres Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours. Kesia Y. Alexander -S for Victor Krauthamer, Ph.D. Acting Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {7}------------------------------------------------ Image /page/7/Picture/1 description: The image shows a logo with the letters OPM. The O is inside a circle, which is inside a square, which is inside a diamond. The P is a circle with a line through it, and the M is a triangle with two lines through it. ### 4 - Indications for Use Statement 510{k) Number (if known): Device Name: OsteoFab™ Patient Specific Cranial Device Indication for Use: The OsteoFab™ Patient Specific Cranial Device (OPSCD) is intended for the replacement of bony voids in the cranial skeleton. Prescription Use V AND/OR (Part 29 CFR 801 Subpart D) Over-The-Counter Use (29 CFR 801 Subpart C) ### (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) *(Division Sign-Off)* Division of Neurological and Physical Medicine Devices 510(k) Number K,121818 Section 4 Page 1 of 1
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...